Tomaz Crochemore: Surviving Sepsis Campaign 2026 – Are We Still Underestimating Hemostasis?
Tomaz Crochemore, Intensivist at Hospital Moriah, Fellow at the University of Zurich, shared a post on LinkedIn about recent article by Hallie C. Prescott et al., published in Intensive Care Medicine:
“Surviving Sepsis Campaign 2026: Are we still underestimating hemostasis?
The new Surviving Sepsis Campaign 2026 guidelines represent an important step forward in many aspects of sepsis care.
But when it comes to hemostasis, a critical gap remains.
The guidelines:
- Recommend restrictive transfusion strategies
- Strongly support pharmacological VTE prophylaxis
- Address bleeding risk (e.g., stress ulcer prophylaxis)
However…
They do not:
- Recognize coagulopathy phenotypes (thrombotic vs hemorrhagic)
- Address the dynamic transition from SIC to DIC
- Incorporate viscoelastic testing or platelet function assessment
- Provide guidance for individualized hemostatic therapy
- Integrate thrombosis and bleeding into a unified clinical frameworkIn other words:
Coagulation is still treated as fragmented events, not as a dynamic system.
Yet we know:
Sepsis is not only inflammation.
It is immunothrombosis.
Patients evolve from:
- early hypercoagulability and fibrinolysis shutdown
- to late hypocoagulability and bleedingManaging only one side of this spectrum is no longer enough.
We are entering a new era where:
- Hemostasis must be continuously assessed
- Coagulopathy phenotypes must be identified
- Therapy must be individualized and time-sensitive
This is not just progress.
This is a paradigm shift.
This is Precision Hemostatic Medicine.
This is Patient Clot Management.
Give your patient only what they truly need.”
Title: Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026
Authors: Hallie C. Prescott, Massimo Antonelli, Waleed Alhazzani, Morten Hylander Møller, Fayez Alshamsi, Luciano C. P. Azevedo, Emilie Belley-Cote, Jan De Waele, Lennie Derde, Joanna C. Dionne, Laura Evans, Hayley B. Gershengorn, Carol L. Hodgson, Kimia Honarmand, Jozef Kesecioglu, Lauralyn McIntyre, Mervyn Mer, Mark E. Nunnally, Simon J. W. Oczkowski, Bram Rochwerg, Olurotimi Olaolu Akinola, Kwame A. Akuamoah-Boateng, Laura Alberto, Derek C. Angus, Yaseen M. Arabi, Elie Azoulay, Maurizio Cecconi, Pauline F. Convocar, Gennaro De Pascale, Kent Doi, Bin Du, Moritoki Egi, Marie-Carmelle Elie-Turenne, Ricard Ferrer, Alison Fox-Robichaud, Craig French, Yonathan Freund, Michelle Ng Gong, Caleb P. Hale, Naomi E. Hammond, Madiha Hashmi, Leo Heunks, Theodore J. Iwashyna, Shevin T. Jacob, Michael Klompas, Arthur Kwizera, Murdoch Leeies, Joanna D. Lejnieks, Mitchell M. Levy, Flavia R. Machado, Marcelo O. Maia, Henry Masur, Ryan C. Maves, Steven McGloughlin, Joanne McPeake, Nicholas M. Mohr, Sheila Nainan Myatra, Marlies Ostermann, Sandra L. Peake, Mathias W. Pletz, Jason A. Roberts, Regis G. Rosa, Robert G. Sawyer, Christa A. Schorr, Steven Q. Simpson, Li Weng, W. Joost Wiersinga, Andrew Rhodes, Craig M. Coopersmith
Stay updated with Hemostasis Today.
-
Jun 7, 2026, 09:26Filimon Dagnew Bezabih: SNMMI Honors 18F-GP1 PET Imaging for Innovation in Thrombosis Detection
-
Jun 7, 2026, 06:57Chandran Nadarajan: Targeted Endovascular Thrombolysis Offers Organ-Saving Benefits in Vascular Occlusions
-
Jun 7, 2026, 05:50Sayan Koley: Lupus Anticoagulant – A Key Marker in Thrombosis Risk Assessment
-
Jun 7, 2026, 05:45Nicolas Hubacz: Watching a Heart Build Its Network
-
Jun 7, 2026, 05:40New Evidence Highlights the Urgent Need for Gender-Inclusive Bleeding Disorders Research – EHC
-
Jun 7, 2026, 03:15Shirley D’Sa: What Comes After BTK Inhibitors in Waldenström Macroglobulinaemia?
-
Jun 6, 2026, 23:30Yazan Abou-Ismail: Insights on A Snail-Derived Potential Anticoagulant with Possibly Improved Bleeding Profile
-
Jun 6, 2026, 18:40Igor Carvalho de Oliveira: The Hidden Genetic Risk Behind Early Heart Attacks and Strokes
-
Jun 6, 2026, 17:39Kalyan Roy: Immunomodulation after Blood Transfusion